Privia Health Group (PRVA) to Release Quarterly Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) is scheduled to be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Privia Health Group has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The business had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. During the same period in the previous year, the firm earned $0.14 EPS. The company’s revenue was up 21.0% on a year-over-year basis. On average, analysts expect Privia Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $19.25 on Wednesday. The company has a 50 day simple moving average of $19.61 and a two-hundred day simple moving average of $21.06. Privia Health Group has a fifty-two week low of $17.54 and a fifty-two week high of $30.15. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of 101.32, a P/E/G ratio of 2.56 and a beta of 0.81.

Insider Transactions at Privia Health Group

In related news, CFO David Mountcastle sold 2,320 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total transaction of $42,734.40. Following the completion of the sale, the chief financial officer now owns 259,959 shares in the company, valued at $4,788,444.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO David Mountcastle sold 2,320 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $42,734.40. Following the completion of the sale, the chief financial officer now directly owns 259,959 shares in the company, valued at $4,788,444.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas Bartrum sold 2,252 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total transaction of $41,481.84. Following the completion of the transaction, the executive vice president now owns 103,862 shares in the company, valued at $1,913,138.04. The disclosure for this sale can be found here. Insiders have sold a total of 31,783 shares of company stock worth $582,886 in the last ninety days. Insiders own 14.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Bank of America cut Privia Health Group from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $27.00 to $21.00 in a research note on Thursday, February 22nd. TD Cowen dropped their price target on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Truist Financial reduced their price objective on shares of Privia Health Group from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Citigroup assumed coverage on shares of Privia Health Group in a report on Monday, April 22nd. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Stifel Nicolaus cut their target price on Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.58.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.